Precision Digital Health Enters into Partnership with Datavant to Enable Real-World Data Linkages within SUMMA Platform

By AIT News Desk On Sep 24, 2020

Precision Digital Health (PDH) announced a strategic partnership enabling PDH to use Datavant’s data linking technology within their SUMMA platform. SUMMA is a cutting-edge Real-World Evidence (RWE) platform that enables life science companies and CROs to integrate and link patient data to support regulatory-compliant research.

This partnership will enable SUMMA to support data flows including de-identified real-world data sourced from Datavant’s open ecosystem. SUMMA now has the ability to link client data from multiple sources, including real world, clinical trials and device data. This integrated solution gives life sciences customers an off-the-shelf system to rapidly ingest, process, and analyze a patient’s longitudinal journey.

Lightning AI Raises $50Million to Simplify and Scale AI Development For Enterprises and Developers

Nov 22, 2024

Teach Mode Is Here: rabbit Gives Consumers Power to Create Custom AI Agents

Nov 22, 2024

Lumina AI Welcomes Jason Sultz to Advisory Board to Strengthen AI and Advanced Compute Expertise

Nov 22, 2024

Prev Next 1 of 40,411

“The ability to seamlessly integrate de-identified real-world data enables life sciences companies to more easily analyze and understand their results,” said Jason LaBonte, Chief Strategy Officer at Datavant. “This partnership will accelerate the pace at which life science companies can ingest and analyze proprietary or third-party data, in turn expediting the clinical and commercial development process and the speed of therapies to market.”

“We are thrilled to partner with Datavant to expand these innovative solutions for our customers,” said Thomas Wells, CEO at PDH. “Complaint data linking enables our clients to better understand and analyze disparate data sources, allowing them to perform more efficient and streamlined clinical research. SUMMA, equipped with this privacy-preserving linking capability, represents a leap forward for the use of real-world data in the clinical setting.”